cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fibrogen Inc
17 own
21 watching
Current Price
$0.37
$-0.02
(-5.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
36.71M
52-Week High
52-Week High
2.93000
52-Week Low
52-Week Low
0.30100
Average Volume
Average Volume
1.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization36.71M
icon52-Week High2.93000
icon52-Week Low0.30100
iconAverage Volume1.2M
iconDividend Yield--
iconP/E Ratio--
What does the Fibrogen Inc do?
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Read More
How much money does Fibrogen Inc make?
News & Events about Fibrogen Inc.
Business Wire
1 year ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (FibroGen or the Company) (NASDAQ: FGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
Benzinga
1 year ago
Earlier today,FibroGen Inc(NASDAQ: FGEN) said its Phase 3 ZEPHYRUS-1 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change in forced vital capacity (FVC) from baseline at week 48 or the secondary endpoint of a decline in FVC percent Latest Ratings ...
Business Wire
1 year ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (FibroGen or the Company) (NASDAQ: FGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
PR Newswire
1 year ago
Thinking about buying stock in Overstock.com, Trxade Health, FibroGen, SAI.TECH, or FingerMotion? Thinking about buying stock in Overstock.com, Trxade Health, FibroGen, SAI.TECH, or FingerMotion? PR Newswire NEW YORK, June 26, 2023 NEW YORK, June 26, 2023 /PRNewswire/ -- InvestorsObserver issues...
Stock Options Channel
1 year ago
Investors considering a purchase of FibroGen Inc (FGEN) shares, but cautious about paying the going market price of 16.62/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at ...
Frequently Asked Questions
Frequently Asked Questions
What is Fibrogen Inc share price today?
plus_minus_icon
Can Indians buy Fibrogen Inc shares?
plus_minus_icon
How can I buy Fibrogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Fibrogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fibrogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Fibrogen Inc?
plus_minus_icon
What is today’s market capitalisation of Fibrogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fibrogen Inc?
plus_minus_icon
What percentage is Fibrogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fibrogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.37
$-0.02
(-5.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$0.70
$-0.00 (-0.57 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.54
$0.04 (1.39 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$127.28
$0.20 (0.16 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.15
$-0.03 (-2.54 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$0.70
$-0.00 (-0.57 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.54
$0.04 (1.39 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$127.28
$0.20 (0.16 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.15
$-0.03 (-2.54 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00